Phase I Study of the Third Generation Adenovirus H5.001CBCFTR in Patients With Cystic Fibrosis

Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients

NCT02965326 ·Status: RECRUITING ·Phase: NA

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473 ·Status: COMPLETED ·Phase: PHASE3

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have a Non-G551D CF Transmembrane Conductance Regulator (CFTR) Gating Mutation

NCT01614470 ·Status: COMPLETED ·Phase: PHASE3

Detection of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity in Rectal Tissues From Human Subjects

NCT01078740 ·Status: COMPLETED

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807923 ·Status: COMPLETED ·Phase: PHASE3

Phase I Study of Liposome-Mediated Gene Transfer in Patients With Cystic Fibrosis

NCT00004806 ·Status: COMPLETED ·Phase: PHASE1

Real-world Efficacy and Safety of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy in Adult Patients With Cystic Fibrosis (CF)

NCT05526027 ·Status: UNKNOWN ·Phase: NA

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

NCT00953706 ·Status: TERMINATED ·Phase: PHASE2

Interest of Gentamicin-induced Readthrough in Cystic Fibrosis Patients

NCT00376428 ·Status: TERMINATED ·Phase: PHASE2

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807949 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

NCT03256799 ·Status: COMPLETED ·Phase: PHASE4

Diagnosis and Treatment of Patients With Cystic Fibrosis

NCT00001223 ·Status: TERMINATED

An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations

NCT02934698 ·Status: COMPLETED ·Phase: PHASE3

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation

NCT00909727 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

NCT02725567 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

NCT02070744 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation

NCT03068312 ·Status: COMPLETED ·Phase: PHASE3

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

NCT01707290 ·Status: COMPLETED ·Phase: PHASE3

Tissue Collection From People With Cystic Fibrosis

NCT00015756 ·Status: COMPLETED

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

NCT02516410 ·Status: COMPLETED ·Phase: PHASE3

A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

NCT02392234 ·Status: COMPLETED ·Phase: PHASE3

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

NCT02347657 ·Status: COMPLETED ·Phase: PHASE3

Modulate-CF: Cystic Fibrosis Transmembrane Regulator (CFTR) Biomarker Study to Evaluate the Rescue of Mutant CFTR in Patients With Cystic Fibrosis Treated With CFTR-modulators

NCT04732910 ·Status: RECRUITING

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

NCT01614457 ·Status: COMPLETED ·Phase: PHASE3

Validation of Therapeutic Efficacy Targeting the Splicing Variants in Cystic Fibrosis and CFTR Pathologies

NCT05100823 ·Status: TERMINATED ·Phase: NA